How to use virological tools for optimal management of chronic hepatitis C

Liver International

Volumn 29, Issue SUPPL. 1, 2009, Pages 9-14

  Chevaliez, Stéphane ^a   Pawlotsky, Jean Michel ^a  

^a French National Reference Center for Viral Hepatitis B C and delta   (France)

Author keywords

Hepatitis C virus; Interferon alpha; Molecular biology; Real time PCR; Ribavin; Serological tests

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CONFERENCE PAPER; DNA DETERMINATION; DRUG RESPONSE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; LOW DRUG DOSE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROGNOSIS; SEROLOGY; VIRUS DETECTION; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; VIRAL LOAD;

EID: 59149099514     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01926.x     Document Type: Conference Paper

References (32)

1. Chevaliez S, Pawlotsky JM. HCV genome and life cycle. In: Tan S-L, ed. Hepatitis C Viruses: Genome and Molecular Biology. Horizon Bioscience, Norwich, UK, 2006; 5-47.
2. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-73.
3. Murphy DG, Chamberland J, Dandavino R, Sablon E. A new genotype of hepatitis C virus originating from central Africa. Hepatology 2007; 46(Suppl. 1): 623A.
4. Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
5. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45: 254-64.
6. Coppola N, Pisapia R, Marrocco C, et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007; 40: 110-5.
7. Hellstrom UB, Sylvan SP, Decker RH, Sonnerborg A. Immunoglobulin M reactivity towards the immunologically active region sp75 of the core protein of hepatitis C virus (HCV) in chronic HCV infection. J Med Virol 1993; 39: 325-32.
8. Negro F, Troonen H, Michel G, et al. Lack of monomeric IgM anti-hepatitis C virus (HCV) core antibodies in patients with chronic HCV infection. J Virol Methods 1996; 60: 179-82.
9. Sagnelli E, Coppola N, Marrocco C, et al. Diagnosis of HCV related acute hepatitis by serial determination of IgM to HCV: A preliminary observation. J Biol Regul Homeost Agents 2003; 17: 207-10.
10. Sagnelli E, Coppola N, Marrocco C, et al. Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol 2005; 42: 646-51.
11. Pawlotsky JM, Prescott L, Simmonds P, et al. Serological determination of hepatitis C virus genotype: Comparison with a standardized genotyping assay. J Clin Microbiol 1997; 35: 1734-9.
12. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36(Suppl. 1): S65-73.
13. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46: 22-31.
14. Sertoz RY, Erensoy S, Pas S, et al. Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother 2005; 17: 514-20.
15. Bouchardeau F, Cantaloube JF, Chevaliez S, et al. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007; 45: 1140-5.
16. Chevaliez S, Bouvier-Alias M, Vandervenet C, Pawlotsky JM. HCV genotype determination in clinical practice: Weaknesses of assays based on the 5′noncoding region and improvement with the core-coding region. Hepatology 2007; 46(Suppl. 1): 839A.
17. Stelzl E, Van Der Meer C, Gouw R, et al. Determination of the hepatitis C virus subtype: Comparison of sequencing and reverse hybridization assays. Clin Chem Lab Med 2007; 45: 167-70.
18. Verbeeck J, Stanley MJ, Shieh J, et al. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 2008; 46: 1901-6.
19. Lok AS, Chien D, Choo QL, et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients. Hepatology 1993; 18: 497-502.
20. Thio CL, Nolt KR, Astemborski J, et al. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000; 38: 575-7.
21. NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consens State Sci Statements 2002; 19: 1-46.
22. Gad RR, Males S, Makhzangy H, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008; 28: 1112-9.
23. Berg T, Von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-97.
24. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-60.
25. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology 2004; 40: 1260-5.
26. Ferenci P, Bergholz U, Laferl H, et al. 24 weeks treatment regimen with peginterferon alpha-2a (40kDa) (Pegasys) plus ribavirin (Copegus) in HCV genotype 1 or 4 "super-responders". J Hepatol 2006; 44: S6.
27. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.
28. Von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522-7.
29. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.
30. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
31. Toyoda H, Kumada T, Kiriyama S, et al. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response. Liver Int 2008 Apr 1 [Epub ahead of print].
32. Fried MW, Hadziyannis SJ, Shiffman M, Messinger D, Zeuzem S. Rapid virological response is a more important predictor of sustained virological response (SVR) than genotype in patients with chronic hepatitis C virus infection. J Hepatol 2008; 48(Suppl. 2): S5.